Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TPX-0046 |
Synonyms | |
Therapy Description |
TPX-0046 inhibits RET and SRC, potentially resulting in decreased tumor cell growth (Annals of Oncology (2019) 30 (suppl_5): v159-v193) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TPX-0046 | TPX0046|TPX 0046 | RET Inhibitor 53 SRC Inhibitor 31 | TPX-0046 inhibits RET and SRC, potentially resulting in decreased tumor cell growth (Annals of Oncology (2019) 30 (suppl_5): v159-v193) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET G810C | Advanced Solid Tumor | predicted - sensitive | TPX-0046 | Preclinical - Cell culture | Actionable | In a preclinical study, TPX-0046 treatment led to inhibition of cell proliferation in a transformed cell line expressing RET G810C in culture (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3616-3616). | detail... |
RET G810R | Advanced Solid Tumor | predicted - sensitive | TPX-0046 | Preclinical - Cell culture | Actionable | In a preclinical study, TPX-0046 treatment led to inhibition of cell proliferation in a transformed cell line expressing RET G810R in culture (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3616-3616). | detail... |
RET G810S | Advanced Solid Tumor | predicted - sensitive | TPX-0046 | Preclinical - Cell culture | Actionable | In a preclinical study, TPX-0046 treatment led to inhibition of cell proliferation in a transformed cell line expressing RET G810S in culture (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3616-3616). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04161391 | Phase Ib/II | TPX-0046 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | Terminated | USA | 1 |